(IZAFE-B) iZafe Series - Ratings and Ratios

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0003656834

IZAFE-B: Medical Dispensers, Digital Services, Drug Management Systems

iZafe Group AB (publ), a Swedish medical technology company, specializes in developing and marketing digital health solutions aimed at improving medication adherence and safety. The companys product portfolio includes Dosell, an automated medication dispenser designed to simplify drug management for patients, and Pilloxa, a digital platform that provides real-time monitoring and data-driven insights to enhance patient engagement and adherence. iZafe Group AB (publ) was established in 2008 and is headquartered in Stockholm, Sweden. The company rebranded from MediRätt AB (publ) to iZafe Group AB (publ) in May 2019, reflecting its expanded focus on innovative digital health solutions. Web URL: https://www.izafe.se

ticker Symbol: IZAFE-B exchange: ST type: common stock country Origin: Sweden gics Sub Industry: Life Sciences Tools & Services

Based on the provided and , the 3-month forecast for iZafe Group AB Series B (ST:IZAFE-B) indicates potential stability with limited upside. The stock is currently trading at 0.25 SEK, with SMA 20 and SMA 50 at 0.25 and 0.23, respectively, suggesting a sideways trend. The ATR of 0.02 reflects low volatility, indicating minimal price fluctuations. On the fundamental side, the high P/B ratio of 8.86 and P/S ratio of 10.84 suggest a premium valuation relative to book value and sales. With a market cap of 86.23M SEK, the stock may face challenges in near-term growth without significant catalysts. Investors should monitor earnings reports and operational updates for potential shifts in momentum.

Additional Sources for IZAFE-B Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

IZAFE-B Stock Overview

Market Cap in USD 8m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception

IZAFE-B Stock Ratings

Growth 5y -70.1%
Fundamental 2.38%
Dividend 0.0%
Rel. Strength Industry 7.45
Analysts -
Fair Price Momentum 0.20 SEK
Fair Price DCF -

IZAFE-B Dividends

No Dividends Paid

IZAFE-B Growth Ratios

Growth Correlation 3m 87%
Growth Correlation 12m 3.2%
Growth Correlation 5y -91.7%
CAGR 5y -30.30%
CAGR/Max DD 5y -0.32
Sharpe Ratio 12m -0.07
Alpha -2.83
Beta 0.87
Volatility 73.43%
Current Volume 141.3k
Average Volume 20d 217.9k
What is the price of IZAFE-B stocks?
As of March 16, 2025, the stock is trading at SEK 0.26 with a total of 141,333 shares traded.
Over the past week, the price has changed by -0.77%, over one month by +8.40%, over three months by +18.35% and over the past year by +8.40%.
Is iZafe Series a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, iZafe Series is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 2.38 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IZAFE-B as of March 2025 is 0.20. This means that IZAFE-B is currently overvalued and has a potential downside of -23.08%.
Is IZAFE-B a buy, sell or hold?
iZafe Series has no consensus analysts rating.
What are the forecast for IZAFE-B stock price target?
According to ValueRays Forecast Model, IZAFE-B iZafe Series will be worth about 0.2 in March 2026. The stock is currently trading at 0.26. This means that the stock has a potential downside of -15.38%.
Issuer Forecast Upside
Wallstreet Target Price 0.3 15.4%
Analysts Target Price - -
ValueRay Target Price 0.2 -15.4%